Acumen Nominates Two EBD Development Candidates for Alzheimer's Treatment
Acumen Pharmaceuticals nominated ACU301 and ACU401 as development candidates combining its amyloid beta oligomer antibodies with JCR Pharmaceuticals' blood-brain barrier penetration technology. The company plans to submit an IND application in mid-2027, expanding its pipeline with a differentiated bispecific antibody approach for Alzheimer's disease.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day